Biggest changeWhile it is often difficult to predict the final outcome or the timing of resolution of any particular tax matter, the Company believes its liability for unrecognized tax benefits is adequate. 19 Table of Contents RESULTS OF OPERATIONS Consolidated Results The table below sets forth for the fiscal years ended April 30, 2024 and 2023, the percentage of consolidated net sales represented by certain items in the Company’s consolidated statements of operations: Fiscal Years Ended April 30, 2024 2023 Revenues FEI-NY 72.9 % 79.2 % FEI-Zyfer 32.8 24.4 Less intersegment revenues (5.7 ) (3.6 ) 100.0 100.0 Cost of revenues 66.4 80.8 Gross margin 33.6 19.2 Selling and administrative expenses 18.4 23.0 Research and development expenses 6.1 7.7 Operating income (loss) 9.1 (11.5 ) Other (expense) income, net 0.8 (1.8 ) (Benefit) Provision from income taxes (0.2 ) 0.2 Net income (loss) 10.1 % (13.5 )% Revenues Fiscal Years Ended April 30, (in thousands) Segment 2024 2023 Change FEI-NY $ 40,261 $ 32,314 $ 7,947 24.6 % FEI-Zyfer 18,138 9,932 8,206 82.6 % Intersegment revenues (3,125 ) (1,469 ) (1,656 ) 112.7 % $ 55,274 $ 40,777 $ 14,497 35.6 % For the fiscal year ended April 30, 2024 revenue increased by approximately $14.5 million, or 36% compared to the prior fiscal year.
Biggest changeRESULTS OF OPERATIONS Consolidated Results The table below sets forth for the fiscal years ended April 30, 2025 and 2024, the percentage of consolidated net sales represented by certain items in the Company’s consolidated statements of operations: Fiscal Years Ended April 30, 2025 2024 Revenues FEI-NY 76.3 % 72.9 % FEI-Zyfer 26.7 32.8 Less intersegment revenues (3.0 ) (5.7 ) 100.0 100.0 Cost of revenues 56.9 66.4 Gross margin 43.1 33.6 Selling and administrative expenses 17.6 18.4 Research and development expenses 8.7 6.1 Operating income 16.8 9.1 Other income, net 0.6 0.8 Benefit from income taxes (16.5 ) (0.2 ) Net income 33.9 % 10.1 % Revenues Fiscal Years Ended April 30, (in thousands) Segment 2025 2024 Change FEI-NY $ 53,269 $ 40,261 $ 13,008 32.3 % FEI-Zyfer 18,660 18,138 522 2.9 % Intersegment revenues (2,118 ) (3,125 ) 1,007 (32.2 )% $ 69,811 $ 55,274 $ 14,537 26.3 % For the fiscal year ended April 30, 2025 revenue increased by approximately $14.5 million, or 26%, compared to the prior fiscal year.
Morion The Company has an investment in Morion, a privately-held Russian company, which manufactures high precision quartz resonators and crystal oscillators. The Company has also licensed certain technology to Morion. The Company’s investment consists of 4.6% of Morion’s outstanding shares, accordingly, the Company accounts for its investment in Morion on the cost basis.
Morion The Company has an investment in Morion, a privately-held Russian company, which manufactures high precision quartz resonators and crystal oscillators. The Company has also licensed certain technology to Morion. The Company’s investment consists of 4.6% of Morion’s outstanding shares, accordingly, the Company accounts for its investment in Morion on a cost basis.
The Company expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. 18 Table of Contents Critical Accounting Estimates The Company’s significant accounting policies are described in Note 1 to the Consolidated Financial Statements.
The Company expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. 17 Table of Contents Critical Accounting Estimates The Company’s significant accounting policies are described in Note 1 to the Consolidated Financial Statements.
The Company believes that its cash, as of April 30, 2024, and cash flows from operations will provide sufficient liquidity to meet its operating needs in the normal course of business in both the short-term (next twelve months from the date of issuance of these consolidated financial statements) and in the long-term (beyond the next twelve months).
The Company believes that its cash, as of April 30, 2025, and cash flows from operations will provide sufficient liquidity to meet its operating needs in the normal course of business in both the short-term (next twelve months from the date of issuance of these consolidated financial statements) and in the long-term (beyond the next twelve months).
The Company is in the process of evaluating the impact that the adoption of ASU No. 2023-09 will have to the financial statements and related disclosures. 23 Table of Contents OTHER MATTERS The financial information reported herein is not necessarily indicative of future operating results or of the future financial condition of the Company.
The Company is in the process of evaluating the impact that the adoption of ASU No. 2023-09 will have to the financial statements and related disclosures. 22 Table of Contents OTHER MATTERS The financial information reported herein is not necessarily indicative of future operating results or of the future financial condition of the Company.
The Company may also pursue acquisitions to expand its range of products and may use internally generated cash and external funding in connection with such acquisitions. During fiscal year 2024, as in fiscal year 2023, the impact of inflation on the Company’s business was due to increases in costs for materials and services.
The Company may also pursue acquisitions to expand its range of products and may use internally generated cash and external funding in connection with such acquisitions . During fiscal year 2025, as in fiscal year 2024, the impact of inflation on the Company’s business was an increases in costs for materials and services.
Other commercial and industrial sales accounted for approximately 6% of consolidated revenues for both fiscal years 2024 and 2023. Sales in the other commercial and industrial sales area were $3.1 million and $2.6 million for the fiscal year ended April 30, 2024 and the fiscal year ended April 30, 2023, respectively.
Other commercial and industrial sales accounted for approximately 3% and 6% of consolidated revenues for fiscal years 2025 and 2024, respectively. Sales in the other commercial and industrial sales area were $2.4 million and $3.1 million for the fiscal year ended April 30, 2025 and the fiscal year ended April 30, 2024, respectively.
For fiscal year 2025, the Company anticipates securing additional customer funding for a portion of its R&D activities and will allocate internal funds depending on market conditions and identification of new opportunities as in fiscal 2024. The Company expects internally generated cash will be adequate to fund these future R&D efforts.
The Company anticipates securing additional customer funding for a portion of its R&D activities and will allocate internal funds depending on market conditions and identification of new opportunities. The Company expects internally generated cash will be adequate to fund these R&D efforts.
During fiscal year 2024, operating cash was increased as a result of decreases in loss on provision accrual and other liabilities and increases in contract assets and inventory, partially offset by an increase in contract liabilities and net income.
During fiscal year 2024, cash flows relating to operating activities increased as a result of decreases in the loss provision accrual and other liabilities and increases in contract assets and inventory, partially offset by an increase in contract liabilities and net income.
Research and Development Expenses Fiscal Years Ended April 30, (in thousands) 2024 2023 Change $ 3,380 $ 3,149 $ 231 7.3 % As a percentage of consolidated revenue, R&D expense for the fiscal years ended April 30, 2024 and 2023 were 6% and 8%, respectively.
Research and Development Expenses Fiscal Years Ended April 30, (in thousands) 2025 2024 Change $ 6,076 $ 3,380 $ 2,696 79.8 % As a percentage of consolidated revenue, R&D expense for the fiscal years ended April 30, 2025 and 2024 were 9% and 6%, respectively.
Morion is a less than wholly-owned subsidiary of Gazprombank, a state-owned Russian bank. The U.S. Ukraine-related sanctions regime has since 2014 included a list of sectoral sanctions identifications (“SSI”) pursuant to Executive Order 13662, which prohibits certain transactions, including certain extensions of credit, with an entity designated as an SSI or certain affiliates of an entity designated as an SSI.
Ukraine-related sanctions regime has since 2014 included a list of sectoral sanctions identifications (“SSI”) pursuant to Executive Order 13662, which prohibits certain transactions, including certain extensions of credit, with an entity designated as an SSI or certain affiliates of an entity designated as an SSI.
Satellite program revenues for government end-use were 40% and 43% of total revenues for fiscal years 2024 and 2023, respectively. Satellite program revenues for commercial end-use were 2% and 1% of total revenue for fiscal years 2024 and 2023, respectively. Revenues on satellite program contracts are recorded in the FEI-NY segment and are recognized primarily under the percentage-of-completion (“POC”) method.
Satellite program revenues for commercial end-use were 6% and 2% of total revenue for fiscal years 2025 and 2024, respectively. 19 Table of Contents Revenues on satellite program contracts are recorded in the FEI-NY segment and are recognized primarily under the percentage-of-completion (“POC”) method. Revenues from non-space U.S.
Revenues from non-space U.S. Government/DOD customers increased by approximately $8.7 million, or 43%, in fiscal year 2024 compared to fiscal year 2023. These revenues are recorded in both the FEI-NY and FEI-Zyfer segments and accounted for approximately 52% and 50% of consolidated revenues for fiscal years 2024 and 2023, respectively.
Government/DOD customers decreased by approximately $2.4 million, or 8%, in fiscal year 2025 compared to fiscal year 2024. These revenues are recorded in both the FEI-NY and FEI-Zyfer segments and accounted for approximately 38% and 52% of consolidated revenues for fiscal years 2025 and 2024, respectively.
The Company’s current ratio at April 30, 2024 was 1.9 to 1 compared to 1.8 to 1, at the end of prior fiscal year. 22 Table of Contents During fiscal years 2024 and 2023, the Company incurred $4.4 million and $5.0 million, respectively, in non-cash charges to earnings, including adjustments relating to net assets and liabilities for operating leases, loss provision accrual, provision for a note receivable, depreciation and amortization expense, inventory adjustments, warranty and accounts receivable reserves and certain employee benefit plan expenses, including accounting for stock-based compensation.
During fiscal years 2025 and 2024, the Company incurred $5.9 million and $4.4 million, respectively, in non-cash charges to earnings, including adjustments relating to net assets and liabilities for operating leases, loss provision accrual, deferred tax assets, depreciation and amortization expense, inventory adjustments, warranty and accounts receivable reserves and certain employee benefit plan expenses, including accounting for stock-based compensation.
The Company believes this may continue to impact expenses in fiscal year 2025 and future years. As of April 30, 2024, the Company had an accumulated deficit of $20.0 million.
The Company believes this may continue to impact expenses in fiscal year 2026 and future years. As of April 30, 2025, the Company had retained earnings of $3.7 million.
(See Note 13 to the Consolidated Financial Statements for a reconciliation of the actual tax benefit to the expected tax provision at the federal statutory rate.) As of April 30, 2024, the Company has U.S. federal net operating losses of $24.2 million of which $8.5 million begins to expire in fiscal year 2025 through fiscal year 2038, including $2.0 million which is subject to annual limitation under Internal Revenue Code Section 382.
(See Note 13 to the Consolidated Financial Statements for a reconciliation of the actual tax benefit to the expected tax provision at the federal statutory rate.) As of April 30, 2025, the Company has U.S. federal net operating losses of $5 million of which $1.7 million begins to expire in fiscal year 2026 through fiscal year 2031.
Tax benefits are recognized for an uncertain tax position when, in the Company’s judgment, it is more likely than not that the position will be sustained upon examination by a taxing authority.
As of April 30, 2025, the deferred tax asset is recorded at its more-likely-than-not realizable amount. 18 Table of Contents Tax benefits are recognized for an uncertain tax position when, in the Company’s judgment, it is more likely than not that the position will be sustained upon examination by a taxing authority.
Net cash used in investing activities for the fiscal year ended April 30, 2024 was $1.5 million compared to $8.7 million provided by investing activities for the fiscal year ended April 30, 2023.
Net cash used in investing activities for the fiscal year ended April 30, 2025 was $1.8 million compared to $1.5 million used in investing activities for the fiscal year ended April 30, 2024 all relating to purchases of capital expenditures .
Income Tax (Benefit) Provision Fiscal Years Ended April 30, (in thousands) 2024 2023 Change $ (130 ) $ 74 $ (204 ) (275.7 )% Fiscal Years Ended April 30, (in thousands) 2024 2023 Effective tax rate on pre-tax book income (loss): (2.4 )% (1.3 )% For the fiscal year ended April 30, 2024, the Company recorded an income tax benefit of $130,000.
Income Tax (Benefit) Provision Fiscal Years Ended April 30, (in thousands) 2025 2024 Change $ (11,542 ) $ (130 ) $ (11,412 ) 8,778.5 % Fiscal Years Ended April 30, (in thousands) 2025 2024 Effective tax rate on pre-tax book income (loss): (95.0 )% (2.4 )% For the fiscal year ended April 30, 2025, the Company recorded an income tax benefit of $11.5 million.
During the fiscal years ended April 30, 2024 and 2023, the Company acquired product from Morion in the aggregate amount of approximately $89,000 and $196,000, respectively. During the fiscal years ended April 30, 2024 and 2023, the Company sold no product and no training services to Morion, and the Company received no dividends from Morion.
During the fiscal year ended April 30, 2025, the Company acquired no product from Morion. During the fiscal year ended April 30, 2024, the Company acquired product from Morion in the aggregate amount of approximately $89,000.
Selling and Administrative Expenses Fiscal Years Ended April 30, (in thousands) 2024 2023 Change $ 10,184 $ 9,372 $ 812 8.7 % In fiscal years ended April 30, 2024 and 2023, selling and administrative expenses (“SG&A”) were 18% and 23% of consolidated revenues, respectively.
Selling and Administrative Expenses Fiscal Years Ended April 30, (in thousands) 2025 2024 Change $ 12,289 $ 10,184 $ 2,105 20.7 % In fiscal years ended April 30, 2025 and 2024, selling and administrative expenses (“SG&A”) were 18% of consolidated revenues in both periods.
The majority of the increase in revenue for fiscal year 2024, as compared to fiscal year 2023, was as a result of an increase in sales in the non-space U.S.
The Company is encouraged by the significant revenue growth compared to the prior fiscal year. The majority of the increase in revenue for fiscal year 2025, as compared to fiscal year 2024, was as a result of an increase in sales in the U.S. Government/DOD Satellite market.
The funds received in connection with customer funded R&D appears in revenues and the associated expenses are included in cost of revenues and are not included in the table above. The Company believes that internally generated cash and cash reserves are adequate to fund its future R&D activity.
The Company expects future R&D investment to be in line with, or even potentially above, historical spending. The funds received in connection with customer funded R&D appears in revenues and the associated expenses are included in cost of revenues and are not included in the table above.
The Company’s balance sheet continues to reflect a highly liquid position with working capital of $27.3 million at April 30, 2024 as compared to $21.0 million at April 30, 2023. Included in working capital at April 30, 2024 was $18.3 million consisting of cash and cash equivalents.
LIQUIDITY AND CAPITAL RESOURCES Net cash used in operations was $1.4 million in fiscal year 2025 compared to net cash provided by operations of $8.7 million in fiscal year 2024. The Company’s balance sheet continues to reflect a highly liquid position with working capital of $29.7 million at April 30, 2025 as compared to $27.3 million at April 30, 2024.
According to OFAC, the Cautionary Letter was issued instead of pursuing a civil monetary penalty or taking other enforcement action. Due to the Russia-Ukraine conflict and resulting sanctions, the future status of FEI’s equity investment in Morion is uncertain.
According to OFAC, the Cautionary Letter was issued instead of pursuing a civil monetary penalty or taking other enforcement action.
Government/DOD market. 20 Table of Contents Gross Profit Fiscal Years Ended April 30, (in thousands) 2024 2023 Change Gross Profit $ 18,583 $ 7,849 $ 10,734 136.8 % Gross Profit Percentage 33.6 % 19.2 % For the fiscal year ended April 30, 2024, the gross profit and gross profit percentage increased as a result of several factors.
Gross Profit Fiscal Years Ended April 30, (in thousands) 2025 2024 Change Gross Profit $ 30,097 $ 18,583 $ 11,514 62.0 % Gross Profit Percentage 43.1 % 33.6 % For the fiscal year ended April 30, 2025, the gross profit and gross profit percentage increased as a result of several factors.
The new guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is evaluating the effect on its consolidated financial statements when adopted in fiscal year 2025 but does not expect the effect to be material.
The new guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We adopted the new standard effective April 30, 2025.
The remaining U.S. federal net operating losses of $15.7 million have an indefinite carry-forward period. The U.S. federal capital loss carry-forward of $0.8 million expires in fiscal years 2025 and 2028. U.S. federal R&D credits of $1.0 million begin to expire in fiscal year 2036 through fiscal year 2040.
The U.S. federal net operating losses of $5 million includes $1.7 million which is subject to an annual limitation under Internal Revenue Code Section 382. The remaining U.S. federal net operating losses of $3.4 million have an indefinite carry-forward period. The U.S. federal capital loss carry-forward of $0.8 million expires in fiscal years 2028.
The Company does not foresee significant additional technical issues regarding these programs as most of these programs have been completed. In addition, the Company has new programs that are progressing well, and the Company anticipates that they will add to the generation of additional revenue and profit.
In addition, the Company has new programs that are progressing well, and the Company anticipates that they will generate additional revenue and profit.
In response to these conditions, in connection with the preparation of the audited financial statements included in the 2022 Form 10-K, the Company impaired its investment in Morion in full. The likelihood of future sales to, purchases, and dividend payments from Morion is questionable.
In response to these conditions, in connection with the preparation of the audited financial statements included in the 2022 Form 10-K, the Company impaired its investment in Morion in full. Prior purchases of materials from Morion consisted mainly of quartz crystal blanks, which were used in the fabrication of quartz resonators. However, on October 30, 2024, the U.S.
The Company’s effective tax rate of (2.4)% for fiscal year 2024 differs from the U.S. federal statutory rate of 21% primarily due to state taxes, an income tax benefit for a reduction in the uncertain tax position liability in connection with the expiration of the statute of limitations, and the reduction in the valuation allowance due to a decrease in the deferred tax asset for which no tax benefit was provided.
For the fiscal year ended April 30, 2024, the Company recorded an income tax benefit of $0.1 million. The Company’s effective tax rate of (95.0)% for fiscal year 2025 differs from the U.S. federal statutory rate of 21% primarily due to a reduction of the valuation allowance.
In fiscal year 2023, investing activities included the proceeds related to sales of marketable securities net of the purchases of marketable securities of $9.6 million and purchases of capital expenditures of $0.9 million. There was no cash used in financing activities for the fiscal year ended April 30, 2024.
Net cash used in financing activities for the fiscal year ended April 30, 2025 was $9.9 million, of which $9.6 million was related to a special cash dividend payment of $1.00 per share of common stock paid on August 29, 2024. There was no cash used in financing activities for the fiscal year ended April 30, 2024.
The majority of the increase in the gross profit percentage, as compared to the prior fiscal year, was in the FEI-NY segment and was attributed to the Company resolving technical issues on some developmental programs from the prior two fiscal years.
The majority of the increase in the gross profit percentage, as compared to the prior fiscal year, was in the FEI-NY segment and was attributed to the Company’s performance on several traditional space programs at higher margins, due to favorable cumulative catch-up adjustments, and those programs progressing ahead of schedule.
Operating Income (Loss) Fiscal Years Ended April 30, (in thousands) 2024 2023 Change $ 5,019 $ (4,672 ) $ 9,691 (207.4 )% For the fiscal year ended April 30, 2024, the Company recorded operating income of $5.0 million compared to an operating loss of $4.7 million in the prior fiscal year.
The Company believes that internally generated cash and cash reserves are adequate to fund its future R&D activity. 20 Table of Contents Operating Income Fiscal Years Ended April 30, (in thousands) 2025 2024 Change $ 11,732 $ 5,019 $ 6,713 133.8 % For the fiscal year ended April 30, 2025, the Company recorded operating income of $11.7 million compared to an operating income of $5.0 million in the prior fiscal year.
Net cash used in financing activities for the fiscal year ended April 30, 2023 was approximately $9.4 million related to a special dividend payout. The Company will continue to expend resources to develop, improve and acquire products for space and other applications, which management believes will result in future growth and profitability.
The Company will continue to expend resources for R&D to develop, improve and acquire products for space applications, guidance and targeting systems, and communication systems that management believes will result in future growth and profitability.
The Company is encouraged by the significant revenue growth in both segments compared to the prior fiscal year. In fiscal year 2024, revenues from satellite programs, one of the Company’s largest business areas, increased by $5.3 million, or 30%, compared to the prior fiscal year.
In fiscal year 2025, revenues from satellite programs, one of the Company’s largest business areas, increased by $17.7 million, or 76%, compared to the prior fiscal year. The increase was due mainly to adjustments in total estimated costs in the current period resulting from efficiencies realized.
The Company funded R&D amount was slightly higher in fiscal year 2024 as compared to the previous fiscal year, reflecting the Company’s commitment to maintaining its technical excellence. The Company expects future R&D investment to be in line with, or even potentially above historical commitments.
The Company funded R&D amount was higher in fiscal year 2025 as compared to the previous fiscal year, partially because the previous fiscal year R&D expenditures was lower than planned and some of the expenses were subsequently captured in fiscal year 2025. The increase in R&D expense also reflects the Company’s commitment to maintaining its technical excellence.
The Company also has state net operating loss carryforwards, and state tax credits that expire in various years and amounts. LIQUIDITY AND CAPITAL RESOURCES Net cash provided by operations was $8.7 million in fiscal year 2024 compared to cash provided by operations of $1.2 million in fiscal year 2023.
U.S. federal R&D credits of $0.7 million begin to expire in fiscal year 2038 through fiscal year 2045. The Company also has state net operating loss carryforwards, and state tax credits that expire in various years and amounts. 21 Table of Contents On July 4, 2025, President Trump signed H.R. 1, the “One Big Beautiful Bill Act”, into law.